Skip to content

COVID-19

2020 saw a major addition to our priorities as the dreadful COVID-19 pandemic struck our nation and the world.

The Team at VIC rapidly pivoted during a couple of crucial weeks in March to address clear unmet medical needs for new diagnostics, treatments and a vaccine for SARS-CoV-2. Most importantly, we leveraged our ongoing Department of Defense funded rapid vaccine development platform, VaxCelerate, to target the coronavirus. To this end we partnered with a new biotechnology company, Voltron Therapeutics Inc., to take our new COVID-19 vaccine, called HaloVax, from bench to bedside on an accelerated timeline.

an informative online resource that:

Highlighted Publications

First published: 29 April 2020 https://doi.org/10.1096/fj.202000919 Eric A. Meyerowitz, Augustin G. L. Vannier, Morgan G. N. Friesen, Sara Schoenfeld, Jeffrey A. Gelfand, Michael V. Callahan, Arthur Y. Kim, Patrick M. Reeves, Mark C. Poznansky

MedRXiv, June 20, 2020. https://doi.org/10.1101/2020.06.19.20135723 

Tyler E Miller, Wilfredo F. Garcia Beltran, Adam Z. Bard, Tasos Gogakos, Melis N Anahtar, Michael G. Astudillo, Diane Yang, Julia Thierauf, Adam S. Fisch, Grace K. Mahowald, Megan J. Fitzpatrick, Valentina Nardi, Jared Feldman, Blake M. Hauser, Timothy M. Caradonna, Hetal D. Marble, Lauren L. Ritterhouse, Sarah E. Turbett, Julie Batten, Nicholas Z. Georgantas, Galit Alter, Aaron G. Schmidt, Jason B. Harris, Jeffrey A. Gelfand, Mark C. Poznansky, Bradley E. Bernstein, David N. Louis, Anand Dighe, Richelle C. Charles, Edward T. Ryan, John A. Branda, Virginia M. Pierce, Mandakolathur R. Murali, A. John Iafrate, Eric S Rosenberg, Jochen Lennerz